Atopic dermatitis (AD) — commonly called eczema — is a chronic inflammatory skin condition affecting approximately 15–20% of children and 2–5% of adults. Most patients are managed with topical therapy and have a relatively low annual cost burden. However, a significant minority with moderate-to-severe disease unresponsive to topicals face a fundamentally different financial profile: the biologics and JAK inhibitors that have transformed AD management over the past decade cost R100,000–R200,000 per year and require exceptional-needs authorisation from every scheme. Understanding this bifurcation — mild disease vs severe biologic-requiring disease — is the central planning challenge for AD patients and their advisors.
What Is Atopic Dermatitis?
AD is driven by immune dysregulation: Th2-pathway overactivation leads to impaired skin barrier function, chronic inflammation, and itch. The itch-scratch cycle perpetuates and worsens skin damage. Key clinical features:
- Chronic, relapsing itch — often the most disabling symptom; significantly disrupts sleep
- Eczematous skin lesions — erythematous, weeping, crusting in acute phases; lichenified (thickened, leathery) in chronic disease
- Distribution by age: Infants — face and scalp; children — flexural (antecubital, popliteal) creases; adults — hands, eyelids, neck, generalised
- Trigger factors: Soap, detergents, sweat, airborne allergens, emotional stress, skin infections (especially Staphylococcus aureus)
AD is the first step in the "atopic march" — the natural history of atopy progressing from eczema in infancy through allergic rhinitis and asthma in childhood/adolescence.
The Treatment Ladder
AD management follows a stepped approach based on disease severity.
Step 1 — All patients: Emollient therapy Daily emollient (moisturiser) application is non-negotiable regardless of severity. It restores skin barrier function, reduces water loss, and diminishes trigger sensitivity. Monthly emollient cost: R300–R600 depending on product volume required. This should be covered from the standard medicine benefit or MSA.
Step 2 — Mild-moderate: Topical corticosteroids (TCS) Hydrocortisone 1% (mild) through betamethasone (potent) applied to active lesions. Stepped by potency: mild preparations for face and sensitive areas; moderate-to-potent for body. Monthly cost: R150–R400. Should be accessible through standard MSA/medicine benefit.
Step 3 — Steroid-sparing: Topical calcineurin inhibitors (TCIs) Tacrolimus ointment (Protopic) and pimecrolimus cream (Elidel). Non-steroidal; preferred for facial and sensitive-area use to avoid corticosteroid-related skin thinning. Monthly cost: R500–R700. Not always on plan formularies.
Step 4 — Moderate-severe, inadequate topical response: Systemic therapy - Cyclosporine (short-term bridge): Potent immunosuppressant; used for 3–6 months during acute severe flares. Monthly cost: R1,000–R1,500. Requires monitoring. - Methotrexate: Off-label; slower onset; monthly cost R300–R500. Used for maintenance in some cases. - Dupilumab (Dupixent): IL-4/IL-13 receptor inhibitor — the most important advance in AD management in 20 years. Biologic; subcutaneous injection every 2 weeks. Monthly cost: ~R14,000. Exceptional-needs authorisation required from all schemes. - Tralokinumab (Adtralza): IL-13 inhibitor; similar efficacy and cost profile to dupilumab. - Upadacitinib (Rinvoq): Oral JAK1 inhibitor; very effective; monthly cost ~R9,000. - Abrocitinib (Cibinqo): Oral JAK1 inhibitor; similar profile to upadacitinib; monthly cost ~R8,500.
Important note: JAK inhibitor SA SAHPRA registration status for AD indication requires verification. Dupilumab is well-established in SA for AD.
Getting Dupilumab Funded: The Exceptional-Needs Application
Dupilumab at ~R14,000/month (R168,000/year) is transformative for severe AD — clear skin in 60–80% of patients who respond. It is also extremely expensive. Every scheme requires an exceptional-needs application. The motivation from your dermatologist must include:
- Confirmed diagnosis of moderate-to-severe AD (EASI score ≥16 or IGA 3–4)
- Documentation of inadequate response or intolerance to at least two topical therapies
- Ideally: prior systemic therapy trialled (cyclosporine, methotrexate) and outcome
- Clinical photographs of current disease state
- Weight and proposed dosing schedule
- Reference to SAHPRA-registered indication for dupilumab in moderate-to-severe AD
Prior failure of systemic therapy (cyclosporine) before dupilumab is required by most schemes — this is the step-therapy requirement. If your child or you has never trialled systemic therapy, the scheme may require this before approving a biologic.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Mild AD — topicals + emollients only | R5,000 – R15,000 |
| Moderate AD — topicals + systemic (cyclosporine/methotrexate) | R20,000 – R50,000 |
| Severe AD — dupilumab | R150,000 – R180,000 |
| Severe AD — JAK inhibitor (upadacitinib/abrocitinib) | R100,000 – R130,000 |
Gap Cover Relevance: Medium
Atopic dermatitis rarely requires hospitalisation. The primary cost driver is biologic medication, not specialist shortfalls. Gap cover is relevant for dermatologist consultation shortfalls but is not the primary financial risk. The biologic cost is the dominant planning factor.
Plan Selection: Key Questions
- What is the exceptional-needs pathway for dupilumab, and what step-therapy is required?
- Is the dermatologist consultation benefit adequate for the quarterly specialist review biologics require?
- Are topical calcineurin inhibitors (tacrolimus, pimecrolimus) on the formulary?
- Is cyclosporine accessible as a bridge therapy for severe flares?
Talk to Eldon
See which plans pay for eczema/atopic dermatitis →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
Infection: The Hidden Cost Driver
Atopic dermatitis dramatically increases the risk of skin infections because the impaired skin barrier allows bacterial and viral invasion. The two most clinically important infectious complications:
Staphylococcus aureus superinfection: Nearly all moderate-to-severe AD patients are colonised with Staph aureus, which perpetuates inflammation. Acute bacterial superinfection (impetigo, spreading erythema, weeping) requires antibiotic treatment — topical fusidic acid for localised infection; oral flucloxacillin, cefalexin, or co-trimoxazole for spreading disease. Recurrent Staph infections significantly add to the annual cost profile.
Eczema herpeticum: Widespread herpes simplex virus infection disseminating through broken eczematous skin. Presents with characteristic punched-out vesicles and pain; can be severe. Requires urgent oral or IV acyclovir. This is a dermatological emergency — seek care immediately if suspected.
These infections can hospitalise patients and generate in-hospital costs well above the routine AD annual budget. Factor this into plan selection (in-hospital benefit adequacy) for moderate-to-severe disease.